VaxThera S.A.S., a Colombian biotechnology company developing and manufacturing vaccines and biological products, has entered into an agreement with Codagenix Inc. to exclusively license its yellow fever vaccine candidate Syn17D-YF (CDX-470).

Under the agreement, VaxThera plans to take Syn17D-YF through manufacturing, preclinical and clinical development, regulatory registration and commercialisation in selected global markets.

Syn17D-YF was developed by Codagenix using its synthetic biology technology. The fully synthetic vaccine is based on the genome sequence of the yellow fever vaccine strain 17D-204 and corresponds to the genome sequence of several established 17D vaccine strains.

The candidate has been shown to be genetically stable and can be produced at high yields using modern cell culture processes. Cell-based manufacturing can also support vaccine virus recovery and purification while reducing the presence of host proteins and DNA from the production process.

Current licensed yellow fever vaccines are manufactured using embryonated chicken eggs, a method that dates back to the 1930s. This production approach can make it more difficult to rapidly increase vaccine supply during outbreaks or periods of increased demand.

Codagenix developed Syn17D-YF to address some of these manufacturing challenges. Earlier attempts to produce updated versions of 17D-204 vaccines using cell culture faced difficulties because of the development of pathogenic mutations during repeated cell culture passages.

VaxThera will use its manufacturing and biotechnology capabilities in Medellín, Colombia, to support the further development of Syn17D-YF. The company has established an integrated biotechnology facility covering research and development, process development, quality control and advanced manufacturing.

Its biologics manufacturing facility has been designed to meet international GMP standards and has the potential to produce more than 150 million vaccine doses annually. The partnership is expected to add manufacturing capacity and improve resilience in the global yellow fever vaccine supply chain.

Yellow fever remains a public health concern in endemic areas of Latin America and sub-Saharan Africa, as well as for international travellers. The World Health Organization’s Eliminate Yellow fever Epidemics (EYE) strategy aims to protect at-risk populations, prevent international spread and support rapid outbreak control through reliable access to affordable vaccines.

In 2025, the Pan American Health Organization issued an epidemiological alert following an increase in confirmed yellow fever cases in several countries in the Americas.

Through the partnership, VaxThera and Codagenix aim to support global public health efforts by developing an alternative manufacturing approach for yellow fever vaccination and strengthening vaccine supply in endemic and non-endemic regions.

 

Source: prnewswire.com

VaxThera S.A.S., a Colombian biotechnology company developing and manufacturing vaccines and biological products, has entered into an agreement with Codagenix Inc. to exclusively license its yellow fever vaccine candidate Syn17D-YF (CDX-470).

Under the agreement, VaxThera plans to take Syn17D-YF through manufacturing, preclinical and clinical development, regulatory registration and commercialisation in selected global markets.

Syn17D-YF was developed by Codagenix using its synthetic biology technology. The fully synthetic vaccine is based on the genome sequence of the yellow fever vaccine strain 17D-204 and corresponds to the genome sequence of several established 17D vaccine strains.

The candidate has been shown to be genetically stable and can be produced at high yields using modern cell culture processes. Cell-based manufacturing can also support vaccine virus recovery and purification while reducing the presence of host proteins and DNA from the production process.

Current licensed yellow fever vaccines are manufactured using embryonated chicken eggs, a method that dates back to the 1930s. This production approach can make it more difficult to rapidly increase vaccine supply during outbreaks or periods of increased demand.

Codagenix developed Syn17D-YF to address some of these manufacturing challenges. Earlier attempts to produce updated versions of 17D-204 vaccines using cell culture faced difficulties because of the development of pathogenic mutations during repeated cell culture passages.

VaxThera will use its manufacturing and biotechnology capabilities in Medellín, Colombia, to support the further development of Syn17D-YF. The company has established an integrated biotechnology facility covering research and development, process development, quality control and advanced manufacturing.

Its biologics manufacturing facility has been designed to meet international GMP standards and has the potential to produce more than 150 million vaccine doses annually. The partnership is expected to add manufacturing capacity and improve resilience in the global yellow fever vaccine supply chain.

Yellow fever remains a public health concern in endemic areas of Latin America and sub-Saharan Africa, as well as for international travellers. The World Health Organization’s Eliminate Yellow fever Epidemics (EYE) strategy aims to protect at-risk populations, prevent international spread and support rapid outbreak control through reliable access to affordable vaccines.

In 2025, the Pan American Health Organization issued an epidemiological alert following an increase in confirmed yellow fever cases in several countries in the Americas.

Through the partnership, VaxThera and Codagenix aim to support global public health efforts by developing an alternative manufacturing approach for yellow fever vaccination and strengthening vaccine supply in endemic and non-endemic regions.

 

Source: prnewswire.com

Report Abuse